Premium
FDA approves esketamine treatment for MDD, suicidal ideation
Author(s) -
Canady Valerie A.
Publication year - 2020
Publication title -
mental health weekly
Language(s) - English
Resource type - Journals
eISSN - 1556-7583
pISSN - 1058-1103
DOI - 10.1002/mhw.32471
Subject(s) - suicidal ideation , food and drug administration , major depressive disorder , medicine , depression (economics) , drug , psychiatry , pharmacology , poison control , emergency medicine , suicide prevention , cognition , economics , macroeconomics
The Food and Drug Administration (FDA) announced Aug. 3 approval of Janssen Pharmaceutical's supplemental new drug application (sNDA) for the expanded use of SPRAVATO esketamine Clll nasal spray for the treatment of major depressive disorder (MDD) with acute suicidal ideation or behavior. SPRAVATO was initially approved by the FDA March 5, 2019, for the treatment of treatment‐resistant depression.